Stoke Therapeutics (STOK) Long-Term Deferred Tax (2018 - 2021)

Stoke Therapeutics has reported Long-Term Deferred Tax for 4 years, with the latest figure at $66.0 million in Q4 2021.

• For the quarter ending Q4 2021, Long-Term Deferred Tax rose 77.42% year-over-year to $66.0 million; the trailing twelve-month figure through Dec 2021 stood at $66.0 million (up 77.42% YoY), and the FY2021 full-year result was $66.0 million, up 77.42% from the prior year.
• Long-Term Deferred Tax for Q4 2021 stood at $66.0 million, up from $37.2 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $66.0 million in Q4 2021, with the low at $7.6 million in Q4 2018.
• Average Long-Term Deferred Tax over 4 years is $32.2 million, with a median of $27.6 million recorded in 2019.
• Year-over-year, Long-Term Deferred Tax jumped 135.53% in 2019 and jumped 77.42% in 2021.
• Tracing STOK's Long-Term Deferred Tax over 4 years: stood at $7.6 million in 2018, then surged by 135.53% to $17.9 million in 2019, then soared by 107.82% to $37.2 million in 2020, then jumped by 77.42% to $66.0 million in 2021.
• The last three Long-Term Deferred Tax figures came in at $66.0 million (Q4 2021), $37.2 million (Q4 2020), and $17.9 million (Q4 2019), per Business Quant data.

Peer Comparison